focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Feb 11, 2021
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule
Jan 26, 2021
Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Jan 15, 2021
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.